Full-Time

Scientific Account Executive

Adaptyv Biosystems

Adaptyv Biosystems

11-50 employees

AI-driven protein design and synthesis platform

No salary listed

Remote in USA

Remote

Category
Sales & Account Management (1)
Required Skills
Biophysics
Biochemistry
REST APIs

Get referred to Adaptyv Biosystems

See people who can refer or advise you

Requirements
  • A scientific background in protein engineering, biochemistry, biophysics, or a related field, with the ability to discuss binding kinetics, expression systems, and assay design.
  • Experience in a customer-facing technical role such as field application scientist, technical sales, scientific account management, or a similar role.
  • The ability to discuss binding kinetics, including KD, kon, and koff, expression systems, and assay design without needing to look them up.
  • Commercial focus on revenue, pipeline, and closing deals.
  • The ability to communicate technical details to scientists and concise business information to vice presidents.
  • The ability to manage an individual pipeline and priorities without heavy oversight.
Responsibilities
  • Own the full customer lifecycle, including prospecting, technical sales conversations, deal closing, onboarding, and ongoing account management.
  • Serve as the technical point of contact for customers, understand their protein engineering goals, and recommend appropriate experiments such as binding, expression, thermostability, and enzyme activity assays.
  • Understand and explain assay capabilities in depth, including BLI, SPR, cell-free expression, and emerging assay types, and determine when each is appropriate and what the data means.
  • Work closely with the biology team to ensure experiments are designed correctly and results are communicated clearly.
  • Build and maintain a pipeline of commercial opportunities across AI-driven protein design companies, biotech startups, pharmaceutical research and development teams, and academic labs.
  • Develop proposals and quotes tailored to customer needs, from small pilot experiments to large-scale data generation campaigns.
  • Represent Adaptyv at conferences and industry events and conduct deep technical conversations with attendees.
  • Feed customer insights back to the product and biology teams, including requested assays, product gaps, and reasons deals are lost.
  • Onboard new customers and help them design their first experiments on the platform.
  • Monitor ongoing accounts, flag issues early, and suggest next steps based on experiment results.
  • Work with the biology team to troubleshoot customer experiments that do not produce expected results.
  • Identify expansion opportunities within existing accounts, including new targets, assay types, and larger campaigns.
Desired Qualifications
  • CRO or biotech vendor experience is a strong plus.
  • Genuine interest in AI-driven protein design and the companies working in this space.

Adaptyv Biosystems designs and sells custom proteins—such as antibodies and enzymes—produced using AI-guided design and cell-free synthetic biology. Its process uses automated workcells to express and test thousands of protein designs on demand, with experimental data feeding back into AI models to improve future designs. A forthcoming AI-enabled foundry will integrate sequencing design, experimental planning, autonomous execution, and data tracking across the protein-engineering cycle. The company aims to shorten development timelines and deliver protein designs that can prevent or treat disease, differentiating itself through end-to-end automation, cell-free expression, and iterative AI optimization.

Company Size

11-50

Company Stage

Series A

Total Funding

$8.5M

Headquarters

Lausanne, Switzerland

Founded

2020

Get referred to Adaptyv Biosystems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Adaptyv's March 2026 hackathons tested 250 proteins and 100 TREM2 designs.
  • The July 2026 Benchling integration expands distribution to more AI and biology teams.
  • The 2025 $8 million seed round funded assay expansion, automation, and API rollout.

What critics are saying

  • Adaptyv still looks small, with roughly 17-31 employees in 2026.
  • Benchling and Tamarind can disintermediate Adaptyv by owning experiment ordering workflows.
  • Protein validation economics depend on expensive wet-lab throughput; margin compression can hit during 2026 scaling.

What makes Adaptyv Biosystems unique

  • Adaptyv launched its public beta and API on April 1, 2026.
  • Benchling named Adaptyv a Direct Ordering Partner in July 2026.
  • Its wet-lab loop returns structured protein data, including KD, kinetics, and melting temperatures.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-2%
StartupTicker
Dec 26th, 2025
CHF 100'000 for Adaptyv Bio and Hexem

Adaptyv Bio: an easier way to engineer proteins using an automated cloud labEpalinges-based Adaptyv Bio has taken protein engineering to a whole new level. Acting as a high-tech protein foundry, the start-up speeds up the design process for proteins. As of today, protein engineering remains a long, very tedious, and expensive task as labs and companies lack the automation and data integration to perform repeatable, scalable protein testing. This is where Adaptyv Bio works its magic: taking advantage of its automated wet lab the company builds a solution for rapid experimental validation of newly designed proteins, while also drastically reducing the costs per protein.
Combined with artificial intelligence, this new technology will make it easier for protein designers to engineer new proteins for a variety of applications, such as designed antibodies, novel enzymes or alternative materials.The Tech Seed loan from FIT will enable Adaptyv to verify the commercial validity of its antibody screening platform and roll out access to the platform at the end of this year.Hexem produces biogas from wastewater cleaningHexem has developed a novel wastewater technology, which produces biogas from industrial waste streams. Its technology uses electrical currents in a bioreactor to clean up contaminated water and produce biogas out of it.
 Nowadays, cleaning industrial wastewater costs enormous amounts of money. Yet, wastewater is an untapped resource containing nutrients and energy alike. Full energy recovery would make wastewater treatment not only energy-neutral but also profitable. And that’s what Hexem enables.The startup’s main users are in the food and beverage industry such as dairies, breweries, wineries and other producers of high strength wastewater like biofuel refineries. With Hexem’s bioreactor installed, they will be able to significantly reduce their water treatment cost and produce clean energy, which can then be reused directly.In the upcoming months, Hexem will build an industrial demonstrator in its container workshop in Port-Valais, thanks to the FIT Tech Seed loan. After ensuring the technical feasibility, this demonstrator will be transferred to an industrial site in Valais.(Press release)

Greater Geneva Bern area (GGBa)
Oct 27th, 2025
Adaptyv Biosystems raises $8M for AI lab

Adaptyv Biosystems, a Vaud-based start-up, has raised $8 million in seed funding to enhance its automated cloud lab for AI-powered protein validation. The funding round was led by ACE Ventures with participation from ByFounders, Founderful, LongGame Ventures, and individual investors. Adaptyv's platform automates the "design–test–learn" cycle, allowing researchers to validate AI-generated protein designs remotely, speeding up the experimental validation process.

BioAlps
Sep 26th, 2025
Adaptyv Raises CHF 6,40 million to Accelerate AI-Driven Protein Validation

Vaud-based startup Adaptyv, specializing in the experimental validation of ai-generated proteins, has raised CHF 6,40 million in seed funding.

StartupTicker
Sep 19th, 2025
Adaptyv Bio Exits Beta, Raises $8M

Adaptyv Bio has officially launched its protein design platform after leaving the beta phase, following an $8 million seed round led by Ace Ventures. The platform, which uses AI to facilitate rapid protein testing and synthesis, has been adopted by over 30 companies, including major pharma firms and AI labs. The funding will help Adaptyv expand its team and infrastructure to meet growing demand.

StartupTicker
Apr 17th, 2023
Adaptyv Bio Launches Its Protein-Engineering Platform

EPFL Spinoff Adaptyv Bio is dedicated to closing the loop between computational prediction and experimental validation with cell-free synthetic biology and high-throughput nanofluidics. Its protein engineering platform is now available in the market.Identifying new antibodies is fundamental in fighting diseases such as viral infections, autoimmune diseases, and cancers. Unfortunately, the current process for testing the efficacy of new antibodies is slow and expensive and has a failure rate of around 88%. Combining robotics, microfluidics and synthetic biology techniques, Adaptyv Bio is building a full-stack platform – protein foundry – that allows protein engineers to design and test new proteins and generate data about their proteins in order to develop new medicines, better enzymes for research and industrial applications or functional materials with novel properties. To enable that tight feedback loop from computational design to experimental validation, Adaptyv is innovating on all levels of the technology stack: from custom synthetic biology techniques for designing DNA, synthesizing proteins and assaying them, to novel lab-on-chip modular work cells that can replace multiple commercial instruments at once, to advanced lab robotics that allow the company to run experiments autonomously. This will reduce reagent consumption, time per experiment and thus cost per data point generated by multiple orders of magnitude compared to today’s approaches